News >

Adjuvant Trials Demonstrate High Clinical Impact in Breast Cancer

Caroline Seymour
Published: Tuesday, Aug 28, 2018

Maryam Nemati Shafaee, MD

Maryam Nemati Shafaee, MD

Clinical trial findings that were presented at the 2018 ASCO Annual Meeting could have a significant impact on patients with early-stage breast cancer in the adjuvant setting, explained Maryam Nemati Shafaee, MD.

State of the Science Summit™ on Breast Cancer, Shafaee, an assistant professor, at the Lester & Sue Smith Breast Center, Duncan Cancer Center, Baylor College of Medicine, discussed the pivotal trials in breast cancer that were reported at the 2018 ASCO Annual Meeting.

OncLive: What were the main updates in breast cancer from the 2018 ASCO Annual Meeting?

Shafaee: The first is the TAILORx trial and the second is the PERSEPHONE trial. There are 2 adjuvant denosumab trials that I also spoke about. TAILORx was a study with a very high clinical impact.

When it comes to premenopausal women or those aged 50 years and younger, it is a little bit different. In this patient population, there was improvement in the outcomes seen in that range, especially between 16 and 20 and 20 and 25. There was about a 7% improved outcome or reduced recurrence risk in the range of 20 to 25. It’s not as clear as it is for patients aged over age 50.

What did we learn from the PERSEPHONE trial?

For PERSEPHONE, researchers looked at DFS in patients with early-stage, HER2-positive breast cancer who would need adjuvant trastuzumab therapy. They looked at 12 months versus 6 months of trastuzumab, which comes to 18 doses versus 9 doses of therapy. They wanted to know whether the 6-month duration was noninferior to the 12-month duration. They reported that the 6-month duration was noninferior to the 12-month duration of trastuzumab.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x